BERLIN, Germany, January 11, 2022 / B3C newswire / -- ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology.
Under this license agreement, Innovent receives non-exclusive rights to use the afucosylation technology GlymaxX for multiple candidates in their pipeline. Therapeutic antibodies with low fucose content show a much higher antibody-dependent cellular cytotoxicity (ADCC) and therefore a higher killing activity against tumorigenic or infected cells. The therapeutic effect can therefore be greatly enhanced. GlymaxX technology is universally applicable, simple and effective and can be integrated into newly developed or already existing cell lines of different origins. In addition, this technology offers flexibility in terms of fucose level adjustment, since only one cell line is sufficient to be used to produce both fucosylated and afucosylated antibodies.
Dr. Gabriele Schneider, Chief Business Officer from ProBioGen stated: "We are very pleased to have Innovent as a new partner for a GlymaxX license. Since its foundation, Innovent has established itself in a very short time as an innovative biopharmaceutical company with its own fully-fledged antibody development platforms and a robust pipeline of antibodies. I am very much looking forward to this collaboration to benefit Innovent's products by the ease of use and high efficacy of our GlymaxX technology."
The GlymaxX technology, developed by ProBioGen, prevents the addition of the sugar "fucose" to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose enhances ADCC (antibody-dependent cell-mediated cytotoxicity) activity for antibodies directed against cancer and infectious diseases. The GlymaxX technology is based on the stable introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis. ProBioGen offers this technology royalty-free to third parties.
ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.
Combining both state-of-the-art development services, based on ProBioGen's CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years. At two locations in Berlin, more than 230 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.
Dr. Gabriele Schneider
Chief Business Officer
+49 (0)30 3229 35 100
Keywords: CHO Cells; Cell Line; Cell Proliferation; Cell Line Development; Cells, Cultured; Recombinant Proteins; Biological Products; Antibodies; Productivity; Antibody-Dependent Cell Cytotoxicity; Fucose; Glycosylation; Technology; Commerce; Licensure; Germany
Published by B3C newswire